Across TCGA pan-cancer cohorts, LINC02508 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LINC02508’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02508 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC02508 is over-expressed in tumor, although a few such as BRCA and KIRP show the opposite, repressed pattern.
BRCA, KIRC, and KIRP are the cancer types where LINC02508 tumor–normal differential expression is most reproducible.